Skip to main content
Clinical Trials/NCT05075187
NCT05075187
Active, Not Recruiting
N/A

Epidemiological Study in FRONtoTemporal Dementia

CENTOGENE GmbH Rostock37 sites in 7 countries4,500 target enrollmentSeptember 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Frontotemporal Dementia
Sponsor
CENTOGENE GmbH Rostock
Enrollment
4500
Locations
37
Primary Endpoint
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Detailed Description

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Registry
clinicaltrials.gov
Start Date
September 1, 2021
End Date
September 30, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
CENTOGENE GmbH Rostock
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
  • The participant is aged between 25 to 85 years
  • The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants

Time Frame: 15 months

Study Sites (37)

Loading locations...

Similar Trials